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Breast cancer tumors have different morphological phenotypes and speciﬁc histopatho-
logical types with particular prognostic and clinical characteristics. The treatment of rare
malignant lesions is frequently controversial due to the absence of trials to determine the
optimal managements. This review describes the spectrum of rare breast tumors indicating
the  clinical, epidemiological and treatment characteristics.eywords:
reast cancer
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2.1.  Pure  tubular  carcinomaeview
.  Background
reast cancer is the most common cause of death from can-
er in women worldwide. In 2012, an estimated of 100,000
ases of invasive breast cancer were diagnosed in the United
tates. The histology type is predominantly ductal in 70–80%
f all cases followed by invasive lobular carcinoma in 5–15%
f patients.1 These tumors had been studied in randomized
rials to determine the optimal treatment approach includ-
ng surgery, endocrine, and chemo or radiation therapy. In
hese types of tumors, the therapeutic approach is generally
ell deﬁned. However, breast tumors exhibit a wide range of
orphological phenotypes and rare speciﬁc histopathological
ypes (less of 2% of all breast cancer) have particular pro-
nostic or clinical characteristics.2–4 Because of the rarity of
hese tumors, there is no consensus regarding optimal treat-
ent and it is difﬁcult to allow large studies to deﬁne theptimal adjuvant treatment. Most cases have been treated
ith standard therapy as there are no data to indicate spe-
ial protocols. The management of uncommon tumors is often
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507-1367/$ – see front matter © 2013 Greater Poland Cancer Centre. Publish
ttp://dx.doi.org/10.1016/j.rpor.2013.08.006controversial due to the lack of large single-institution studies
or randomized trials to deﬁne optimal treatment. In this arti-
cle, we  describe the spectrum of rare breast tumors indicating
the clinical, epidemiological and treatment characteristics.2
Including all the histological types, Ellis et al.5 compared
10-year survival in 1621 cases of primary breast cancer. Ductal
carcinoma in situ, cribriform and tubular carcinoma pre-
sented excellent prognoses, with 10-year survival rates of
92%, 91% and 90%, respectively, compared to 80% for muci-
nous carcinoma, 51% for medullary carcinoma, 54% for lobular
carcinoma and 47% for invasive ductal carcinoma. Table 1
summarizes the main rare breast cancer classiﬁed in epithelial
and non-epithelial breast tumors. Additionally, Table 2 shows
the main characteristics of rare breast cancers.
2.  Rare  epithelial  breast  cancersión Valle del Lili, Av. Simón Bolívar Cra 98 18-49, Cali, Colombia.
Pure tubular carcinoma is a very rare breast cancer that
accounts for less than 2% of invasive breast cancers in most
ed by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
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Table 1 – Rare breast cancer classiﬁed in epithelial and
non-epithelial breast tumors.
Rare epithelial breast cancer
Tubular carcinoma
Invasive cribriform carcinoma
Mucinous carcinoma
Invasive solid papillary carcinoma
Apocrine carcinoma
Neuroendocrine tumors
Medullary carcinoma
Secretory breast carcinoma
Adenoid cystic carcinoma
Acinic cell carcinoma
Metaplastic carcinoma
Glycogen-rich clear-cell carcinoma
Oncocytic carcinoma (malignant oncocytoma)
Sebaceous carcinoma
Primary squamous cell carcinoma
Pleomorphic variant of lobular carcinoma
Papillary Carcinoma of the Breast
Rare non-epithelial breast cancer
Sarcomas
Phylloides tumor
Lymphomas
clinical series. This speciﬁc histological type is more  likely to
occur in older patients, and it is characterized by small size
(the majority are less than 1 cm), and less nodal involvement.6
This tumor is nearly always estrogen (ER) and progesterone
receptor (PR)-positive, well-differentiated, and mostly human
epidermal growth factor receptor type 2 (HER2)-negative.
Patients with pure tubular carcinoma have an excellent prog-
nosis compared with invasive ductal carcinoma with low
ipsilateral recurrence rates. Therapy is based on radiation
treatment after breast conserving surgery.7 The effect of
adjuvant radiotherapy reducing local failure following breast
conservative surgery has been described in the literature.6 Due
to the excellent survival rate of patients with breast tubu-
lar cancer, the need of axillary staging in these patients is
questionable.6 However, the incidence of axillary metastases
may range from 4% to 17%.4,8 Thus, the use of sentinel lymph
node biopsy (SLNB) should be considered for patients with
tubular carcinoma if the positive biopsy ﬁnding will modify
adjuvant treatment.2 However, the survival of patients with
tubular carcinoma is similar to that of the general population,
and there is no evidence that adjuvant therapy due to positive
SLNB inﬂuences survival.6
2.2.  Invasive  cribriform  carcinoma
Breast invasive cribriform carcinoma (ICC) is a rare tumor
reported to range from 0.3% to 3.5% of all breast cancers.
The new deﬁnition of the World Health Organization (WHO)
describes pure ICC as a carcinoma with inﬁltrating compo-
nents presenting more  than 90% of cells of invasive cribriform
pattern.9 The tumor may present as a frequently occult mass,
difﬁcult for radiological detecting. For this reason, the lesions
are usually large at presentation although they grow slowly.
ER and PR expression is common in these tumors. Prognosis
of ICC is excellent, approaching that of the general population
mainly in pure ICC tumors.10 At present, distant metastasis
of pure ICC has rarely been reported. Treatment guidelinesiotherapy 1 9 ( 2 0 1 4 ) 267–274
are extrapolated from other breast cancers without clear vali-
dation.
2.3.  Mucinous  carcinoma
This rare tumor accounts for 1–4% of breast tumors and is
characterized by a better prognosis than inﬁltrative ductal
cancer.11 This breast type is characterized by production of
abundant extracellular and/or intracellular mucin. Pure and
mixed variants of mucinous carcinoma have been described.
The pure type consists of tumor tissue with extracellular
mucin production (90% purity), while the ‘mixed’ form of
mucinous carcinoma (50–90% purity) also contains inﬁltrat-
ing ductal epithelial component without mucin.12 The pure
type shows a better differentiation with low grade and expres-
sion of ER (to 94%) and PR (80%) and the majority of cases.
Compared to inﬁltrating ductal carcinoma, mucin tumors are
smaller and present less nodal involvement.2
The diagnosis age ranges from 25 to 85 years, with a median
age at diagnosis of 71 years in a large retrospective review
of 11,400 breast cancer cases.2 Clinically, mucinous carci-
noma manifests as a palpable lump, with a mammographic
appearance of well-deﬁned and lobulated lesion. Due to the
benign course, a late diagnosis does not worsen the clinical
outcome.13 This benign pattern is conﬁrmed in a large retro-
spective series that shows that 10-year survival is more  than
90%.2 Only 3–15% of the pure variety of mucinous carcino-
mas  show axillary node metastases compared to 33–46% of
the mixed type.8 This involvement is a marker of poor prog-
nosis. However the incidence of nodal involvement is less
that 5% in mucinous tumor of ≤1 cm of diameter. Thus, some
authors recommend that axillary node staging is not beneﬁcial
in tumors measuring less of 1 cm.8 Nevertheless, SLNB should
be considered also in these cases because positive nodal status
seems to be the most important factor associated with worse
prognosis. Patients with pure mucinous carcinomas without
skin invasion are candidates for a breast-conserving therapy.
Concerning the systemic adjuvant therapy, there are no con-
sensus, thus the treatment is based on classical breast cancer
strategies.2
2.4.  Solid  papillary  carcinoma
Solid papillary carcinomas of the breast are rare tumors (to
1.7% of all breast cancers), characterized by round, well-
deﬁned nodules composed of low-grade ductal cells separated
by ﬁbrovascular cores. Pathologically, solid papillary carcino-
mas  exhibit low-grade features, and the tumors often display
neuroendocrine and mucinous differentiation.14 ER and PR are
generally positives and her2 negative. Clinically, these tumors
present as a palpable, centrally located mass or as bloody nip-
ple discharge and affects older women (mean age 66 years).
The most common mammographic appearance of a papil-
lary tumor is as a soft-tissue mass, with calciﬁcation present
in less than half of cases.15 The treatment for solid papil-
lary carcinomas is based on surgical excision. When invasive
carcinoma is not present, the prognosis is excellent.14 There
are limited studies focused solely on treatment strategies for
papillary carcinoma. The absence of deﬁnitive guidelines for
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Table 2 – Main characteristics of rare breast cancers.
Type tumor %a Main histological characteristics ER EP HER2 Clinical features Nodal invasion Prognosis
Pure tubular
carcinoma
2  Haphazardly arranged, inﬁltrative ducts
well formed, uniform in size, and
separated by abundant desmoplastic
ﬁbrous stroma
+  + − Small size mass Low (4–17%) Excellent
Invasive cribriform
carcinoma
0.3–3  Inﬁltrating components presenting more
of 90% of predominantly arranged in a
sieve-like or cribriform growth pattern
+  (96%) + (86%) − (98%) Frequently clinically occult Low Excellent
Mucinous 1–4 Abundant production of extracellular
and/or intracellular mucin
+  (96%) + (80%) − A palpable lump, with a
mammographic
appearance of well-deﬁned
and lobulated lesion
Low (3–15%) Benign
pattern,
10-year
survival > 90%
Solid papillary 1.7 Round, well-deﬁned nodules composed of
low-grade ductal cells separated by
ﬁbrovascular cores. It presents low-grade
features, with neuroendocrine and
mucinous differentiation
+  NA NA Palpable, centrally located
mass or as bloody nipple
discharge and affects older
women
Low (13%) Excellent
Apocrine 0.3–4 Apocrine cells show large round nuclei
and plump, eosinophilic, granular and
sharp-bordered cytoplasm.
−  − + Small size mass Low Favorable
Neuroendocrine 0.1 Neuroendocrine markers (mainly
chromogranin or synaptophysine) in
more than 50% of cells.
+  + − Undistinguished from other
breast cancer types
Low Uncertain
Medullary 5 Solid sheets within an indistinct cell
border (syncytial growth pattern), large
vesicular nuclei and prominent nucleoli,
a broad pushing margin, and an
important lymphocytic inﬁltrate both at
the periphery and within the tumor
−  − − Well delineated and soft on
palpation
Low  (16–21%) Favorable
Secretory Rare Histologically, it belongs to the
phenotypic spectrum of basal-like breast
carcinomas, with intracellular and
extracellular secretory material
−  − − Painless and ﬁrm mass Low Indolent
course
Adenoid cystic 0.1 Cribriform, tubular or solid cells − − − Unilateral, small breast
lump
Low (2%) Favorable
Abbreviations:  ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; NA, not available.
a Percentage of all breast cancers.
d rad270  reports of practical oncology an
management underscores the need for further treatment and
outcome-related studies related to papillary carcinoma.
2.5.  Apocrine  carcinoma
Reported frequency of apocrine carcinoma in breast can-
cer ranges from 0.3% to 4% of all breast cancer patients,16
due probably to pathologist observations. Apocrine breast
carcinoma is a microscopically deﬁned type of invasive duc-
tal carcinoma.16,17 Clinically, apocrine carcinomas usually
present with palpable mass, tend to be unilateral but are
frequently multifocal/multicentric. Histologically, the apoc-
rine cells show large round nuclei and plump, eosinophilic,
granular and sharp-bordered cytoplasm. The tumor expresses
mainly androgen receptor (AR), while ER and PR are absent.17
On the other hand, over-expression of HER2 is frequently
seen.16 This type of tumor shows a favorable prognosis.18 Also
for the apocrine HER2 negative cancer, a better outcome is
suggested compared with triple negative non apocrine can-
cer due to a lower proliferation rate. There are not treatment
recommendations. Hormone therapy targeted against AR may
be applicable. For the triple negative apocrine, chemotherapy
should be chosen.16
2.6.  Neuroendocrine  tumors
Breast localization of neuroendocrine tumors is rare. It rep-
resents less than 0.1% of all breast cancers and less than
1% of all neuroendocrine tumors.19 They are characterized
by neuroendocrine markers (mainly chromogranin or synap-
tophysine) in more  than 50% of cells according to the OMS
classiﬁcation.20,21 Clinical presentation is undistinguished
from other breast cancer types, with a palpable mass, well-
deﬁned by imaging studies.22 HER2 expression is generally
negative, while hormone-receptors are positive. Treatment is
based on surgery, with the same indications for chemother-
apy and radiotherapy as for other breast cancers. Prognosis is
uncertain due to the reduced number of tumors.
2.7.  Medullary  carcinoma
The medullary cancer is a relatively infrequent histological
form of invasive breast cancer representing approximately 5%
of all types.6 These tumor may be deﬁned as classical (present
in the entire lesion),23 or atypical tumor if a less lymphocytic
inﬁltrate is present.24,25 In this type of mutation-associated
tumors, the presence of medullary or atypical medullary
carcinoma is associated with favorable prognosis in this spe-
ciﬁc setting. Patients with medullary carcinoma are generally
younger at the time of diagnosis than patients with inﬁltrating
ductal carcinoma. The mean age of the women ranges from
45 to 52 years.2 Clinically, the tumor is well delineated and
soft on palpation. ER and HER2 are generally negative, and p53
mutations are positive.2 Prognosis in medullary carcinomas is
more  favorable compared with inﬁltrating ductal carcinoma.26The incidence of lymph node compromise is low (from 16% to
21%) compared to other breast cancers.2 BCRA 1 tumors with
high tumor grade, hormone receptor negativity and somatic
p53 mutation are characterized by a worse prognosis.25iotherapy 1 9 ( 2 0 1 4 ) 267–274
Axillary nodal staging and adjuvant radiotherapy following
breast conserving surgery are indicated in these patients.
2.8.  Secretory  breast  carcinoma
Secretory carcinoma of the breast is a rare breast cancer
accounting for less than 0.15% of all breast cancers; it is
associated with incidence at a young age and an indolent
course. Histologically, secretory breast carcinoma belongs to
the phenotypic spectrum of basal-like breast carcinomas,
characterized by the presence of intracellular and extracel-
lular secretory material. A painless and ﬁrm mass is the
predominant form of clinical presentation. Most cases are neg-
ative for ER, PR and HER2. A basal-like marker (epidermal
growth factor receptor is found in around 90% of cases. The
reported incidence rate of axillary lymph node metastasis of
secretory breast carcinoma is 15–30%. Studies have shown that
lymph node metastasis is rare in children and teenagers.27
Sentinel lymph node biopsy has proven to be a useful eval-
uation method for the lymph node status of secretory breast
carcinoma. There is no consensus on this tumor. Most children
and adults have been treated by surgical excision techniques
ranging from local resection to radical mastectomy. The real
value of postoperative radiotherapy and chemotherapy has
not been examined. This tumor is associated with good long-
term survival.
2.9.  Adenoid  cystic  carcinoma
Adenoid cystic carcinoma (ACC) of the breast is a very rare
tumor that is responsible for less than 0.1% of all breast
cancers.28 ACC of the breast may be histologically classiﬁed
as cribriform, tubular or solid. The cribriform type is the most
symptomatic and most frequently presented. ACC affects
women with mean age of 50–65 years.29 This tumor presents
as unilateral, small breast lump of 2 to 3 cm in diameter. ER,
PR and HER2 expression are mostly negative.28 The prognosis
of ACC is favorable, with uncommon lymph nodes invasion of
distant metastases. Axillary nodal involvement is reported in
between 0.8% and 2% of ACC cases and distant metastases
(mainly pulmonary metastases) are present in up to 9% of
cases.28,30,31 A better prognosis is observed in patients with
negative hormone receptor expression. The treatment is based
on surgical and adjuvant radiotherapy. The surgical treatment
ranges from local excision to radical mastectomy.28,30 The role
of radiotherapy has been evaluated after surgery. The series
by Khanﬁr et al.28 shows the results of radiotherapy in 40 ACC
patients treated surgically (35 after lumpectomy, 5 after mas-
tectomy). In the conservative group, radiotherapy improved
5-year loco-regional control from 83% to 95% (p = 0.03) to war-
rant a conclusion that breast-conserving surgery followed by
adjuvant radiotherapy is the treatment of choice for patients
with ACC breast cancer.28
According to the pathological grading from I to III (deﬁned
by the proportion of solid growth elements), the proposed
treatment is lumpectomy for grade I, simple mastectomy
for grade II tumors and mastectomy with axillary clearance
for grade III tumors.29 Radical mastectomy is not advised
due to the low incidence of nodal metastasis. Concerning
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djuvant chemotherapy, endocrine or biological therapies for
CC, there are few studies, and their use is not recommended.
.10.  Acinic  cell  carcinoma
cinic cell carcinoma of the breast with features of acinar-
ype differentiation was ﬁrst described by Roncaroli et al.32
n 1996 as the breast counterpart of identical tumors of the
arotid gland. It is a very rare tumor. After this ﬁrst descrip-
ion, approximately eighteen cases of acinar cell-like breast
arcinoma have been reported.33,34 In image,  a well-deﬁned
ass is observed and mean-age at presentation reported in
he literature is 56 years.35,36 Pathological ﬁndings are dif-
use inﬁltrative growth patterns of small glandular structures
omposed of cells with a coarse granular or clear cytoplasm
esembling acinar cells of the salivary glands. ER, RP and HER2
re regularly negative. Although considered as a tumor of good
rognosis, systemic and local recurrence are described.1,35,36
n view of the small number of cases and short follow-up
eriod, there is no treatment consensus.
.11.  Metaplastic  carcinoma
etaplastic breast carcinoma (MBC) is a rare malignancy
haracterized by histologic presence of two or more  cellular
ypes, commonly a mixture of malignant epithelial and mes-
nchymal components (sarcoma type).37,38 MBC represents
.25–1% of breast cancers diagnosed annually.37 In compari-
on to classical breast adenocarcinomas, tumor size is usually
reater. Median size of the tumor was reported to be in the
ange of 3.4–5.0 cm in some series.39–42 The incidence of axil-
ary lymph node involvement is less in MBC  cases.40,43 The
edian age of MBC  patients was over 50 years of age in the
iterature.39,41,44 Hormone and HER2 receptor positivity rates
re also lower (0–26% for hormone receptors).37 These tumors
ave a poor prognosis due to the high metastatic and recur-
ence potential. Concerning the treatment options, classical
urgery techniques such as radical mastectomy and modiﬁed
adical mastectomy, including axillary dissection, are the pre-
erred surgery choices in the literature.1,37,41 In routine clinical
ractice, there is no standard treatment regimen speciﬁc for
BC  or its subgroups, so clinical practice guidelines for inva-
ive breast adenocarcinoma is mostly used instead.37
.12.  Pleomorphic  variant  of  lobular  carcinoma  (PLC)
his tumor represents a rare variant of invasive lobular car-
inoma, accounting only for 0.97% of all breast carcinomas
nd less than 5% of lobular carcinomas.45 Histology is char-
cterized by eosinophilic cytoplasma and large pleomorphic
ypercromatin nuclei. The mean age at presentation is 58.9
ears (range from 24 to 94 years) with multifocal and bilat-
ral localization.45,46 The tumor presents higher Ki67 index,
ow ER and PR expression and high HER2 ampliﬁcation. This
umor has an aggressive clinical course and poor prognosis.
he treatment strategy is similar to that in other invasive lob-
lar carcinomas.therapy 1 9 ( 2 0 1 4 ) 267–274 271
2.13.  Papillary  carcinoma  of  the  breast
Papillary breast cancer accounts for 0.5% of all invasive breast
cancers. The tumor is characterized by proliferative cells
arranged around ﬁbrovascular cores, forming a circumscribed
mass.47 Papillary breast cancer includes different histologi-
cal types: ductal carcinoma in situ arising in an intraductal
papilloma, papillary ductal carcinoma in situ, encapsulated
papillary carcinoma, solid and invasive papillary carcinoma.
The benign intraductal papillomas present a myoepithelial
cell layer within the papillae, which is different from malig-
nant papillary proliferation that lacks this layer. Clinically,
papillary breast tumors are manifested with bloody nipple dis-
charge, abnormal mass or mammographic abnormalities.48
The ER and PR are usually positive and HER2 negative. The
tumor has a good prognosis. A new treatment approach is not
described in the literature at this moment.
3.  Rare  non-epithelial  breast  cancer
3.1.  Sarcomas
Sarcomas of the breast are a rare group of diverse mes-
enchymal tumors accounting for less than 1% of all
breast tumors. Several histological types including ﬁbrosar-
coma, malignant ﬁbrous histiocytoma, liposarcoma, rhab-
domyosarcoma, leiomyosarcoma, hemangiosarcoma, malig-
nant schwannoma, osteogenic sarcoma and chondrosarcoma
have been described.49 The tumor occurs in the ﬁfth and sixth
decades of life and clinically presents as a painless breast
lump.50 The size of tumor may range from less than 1 cm to
more than 40 cm.  The prognosis of primary breast sarcomas
depends on the size and the histological grade. The tumors
may spread by direct of hematogenous invasion.51,52 However,
axillary nodal involvement is rare.50,53
Treatment is based on a multidisciplinary approach
including surgery, radiation and chemotherapy. In a small ret-
rospective series of the National Cancer Institute, the role of
the adjuvant radiotherapy to treat patients with high-grade
non-metastastatic primary sarcoma was evaluated. In this
study, the prognosis of breast sarcoma was similar to that of
extremity, after 99 months of follow-up. When radiotherapy
was added, excellent control was achieved. In the next section,
some of the histological types of primary breast sarcomas are
described.
. Primary breast ﬁbrosarcoma is a rare neoplasm with not
established incidence. Clinically, this tumor presents as a
lump that may be painful in one-third of cases.
b. Primary leiomyosarcoma of the breast: This tumor is a rare
neoplasm, with less than 20 reported cases in the medical
literature.52 This tumor resembles clinically a malignant
phyllodes tumor, with a ﬁrm lobulated mass. Surgery is
the main approach to treatment. Because leiomyosarcoma
often invades peripheral tissues, such as the skin and
fascia, curative surgery requires a wide resection. The axil-
lary block dissection is usually not recommended, since
none of the reported cases have shown nodal metastases.52
Metastatic spreading usually occurs via the hematogenous
272  reports of practical oncology and radiotherapy 1 9 ( 2 0 1 4 ) 267–274
Table 3 – Adjuvant therapy for rare breast tumors.
Histologic type Radiotherapy Chemotherapy Endocrine therapyb
Tubular carcinoma Useful Usefula Useful
Invasive cribriform carcinoma Useful Usefula Useful
Mucinous carcinoma Useful Usefula Useful
Invasive solid papillary Useful Usefula Useful
Apocrine carcinoma Useful Useful Usefulc
Neuroendocrine tumors Useful Usefula Useful
Medullary carcinomad Useful Usefula Useful
Secretory breast carcinomad Useful Usefula Useful
Adenoid cystic carcinomad Useful Usefula Useful
Acinic cell carcinomad Useful Usefula Useful
Metaplastic carcinomad Useful Useful Useful
Pleomorphic variant of lobular carcinomad Useful Useful Useful
Papillary carcinoma Useful Usefula Useful
Sarcoma Useful Useful Not applicable
Phylloides tumor Useful Useful Not applicable
Lymphoma Useful Useful Not applicable
a Chemotherapy may not be needed.
b For hormone-receptor-positive breast cancers.
c Androgen receptor as a targeted therapy.
d Mostly hormone receptor negative.
route. The beneﬁts of chemotherapy and radiotherapy have
not been conﬁrmed yet.53 Compared to other breast sarco-
mas, the prognosis of leiomyosarcoma is better. However,
long-term follow-up is recommended because local recur-
rence and distant metastases may appear up to 20 years.52
3.1.1.  Primary  breast  lymphoma
The primary breast lymphoma (PBL) is a malignant lymphoma
primarily occurring in the breast in the absence of previously
detected lymphoma in other localizations. It accounts for less
than 0.5% of all malignant lymphomas.54 B-cell lymphoma is
more  frequently observed than T-cell lymphoma in the breast.
Histologies like, follicular non-Hodgkin’s lymphoma or extran-
odal marginal zone (MALT) lymphoma occur less commonly.55
The usual clinical feature of breast lymphoma is a rapidly
expanding, painless mass.54 The differentiation between pri-
mary  and secondary lymphoma is difﬁcult, and some criteria
are used to determine the primary localization of breast lym-
phoma:
1. The availability of adequate pathology material.
2. Both mammary  tissue and lymphomatous inﬁltrate are
present.
3. No widespread disease or preceding extramammary lym-
phoma.
4. Ipsilateral axillary node involvement is considered
acceptable.56
Treatment options include surgery, chemotherapy and
radiation therapy. There is no agreement on the appropri-
ate treatment. Recommendation of chemotherapy for bulky
or stage II disease are founded in the literature. Radiothe-
rapy can be used to provide local control or may be adjuvant
54to chemotherapy. Clinical series show that overall 5-year
survival of 53%. Factors inﬂuencing a better prognosis are:
early stage, conservative surgery, radiotherapy, and combined
modality.573.1.2.  Phyllodes  tumor
Phyllodes tumors account for less than 1% of all primary breast
neoplasms. These tumors are biphasic neoplasms, basically
analogous to ﬁbroadenomas, composed of stromal and epithe-
lial elements. Phyllodes tumors exist in benign (35–64%),
borderline, and malignant subtypes, although there is no uni-
form agreement on the criteria for assigning a subtype or for
predicting biological behavior.4 A subtype of phyllodes tumors
appears to be less important for the risk of recurrence than
does the margin of tumor-free resection achieved by surgical
treatment. Phyllodes tumors are usually benign, but recurr-
ences are not uncommon, and a relatively small number of
patients will develop hamatogenous metastases.
Generally, phyllodes tumor presents as a rapidly grow-
ing and clinically benign breast lump in females within the
4th or 5th decade of life.57 Diagnosis of phyllodes tumor
prior to excisional biopsy/lumpectomy is uncommon. Phyl-
lodes tumors often appear on ultrasound and mammography
as ﬁbroadenomas, and core needle biopsy seems inadequate
to reliably distinguish phyllodes tumor from ﬁbroadenoma.4
Local recurrences of phyllodes tumors are the most common
site of recurrence. Positive margins, ﬁbroproliferation in the
surrounding breast tissue, and necrosis are associated with
a marked increase in local recurrence rates. Most distant
recurrences occur in the lung, and may be solid nodules or
thin-walled cavities. Patients with stromal overgrowth, par-
ticularly with tumor size >5 cm,  have shown a high rate of
distant failure. Death from phyllodes tumor is rare (2%), and
only phyllodes tumors that demonstrate uniformly aggressive
pathologic features seem to be associated with mortality. Wide
local excision with tumor-free margins of 1 cm or greater is the
preferred surgical therapy for patients with phyllodes tumors
regardless of the histological subtype. Total mastectomy is
necessary only if negative margins cannot be obtained by
breast conserving surgery.58,59 Since phyllodes tumors rarely
metastasize to the axillary lymph nodes (10–15%), surgical
axillary staging is not necessary unless the lymph nodes are
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athologic on clinical examination.59 The role of adjuvant
adiotherapy is uncertain and requires further investigation.57
here are only few reported successful treatments with post-
perative irradiation in malignant phyllodes tumors,4 its role
emaining undeﬁned because of the rarity of the condition. A
rospective clinical trial, ‘Phase II study of adjuvant radiothe-
apy after resection in patients with borderline or malignant
hyllodes tumors of the breast’, was initiated by the American
ational Cancer Institute in 1998.2 A total of 50 patients should
ave been accrued for this study within 6–7 years; however, the
tudy is still active for recruitment. While the epithelial com-
onent of most phyllodes tumors contains ER (58%) and/or
R (75%), endocrine therapy has no proven role in the treat-
ent of phyllodes tumors. Similarly, there is no evidence that
djuvant cytotoxic chemotherapy provides a beneﬁt in reduc-
ng recurrences or death. In those patients who experience a
ocal recurrence, resection of the recurrence with wide tumor-
ree surgical margins should be performed. Some members of
he NCCN Panel recommend local radiation therapy follow-
ng resection of a local recurrence, but this recommendation
s controversial. The German panel discussed chemotherapy
nd radiotherapy as an option after R1 resection for local
ecurrence but gave no general recommendation for these
herapies.
In summary, despite a less aggressive treatment, the sur-
ival for the described favorable histological subtypes appears
o be very high, even comparable with that of women with-
ut breast cancer. After adjustment for age, stage, and grade,
atients with tubular, mucinous, and medullary carcinoma,
r malignant phyllodes tumors exhibited such a low risk
f death that in some cases even less aggressive treatment
hould be considered. Because of the rarity of these tumors,
he treatment recommendations have been extrapolated from
ommon breast tumors (Table 3). Patients with these speciﬁc
istological types should be informed of this relatively favor-
ble prognosis.2
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